Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

PT-141

Sexual / aestheticFDA approvedPubMed records: 60count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O PT-141 (Bremelanotida), comercializado como Vyleesi, é um heptapeptídeo cíclico que atua como agonista do receptor melanocortina 4 (MC4R) no sistema nervoso central. Diferentemente de medicamentos vasculares como sildenafil, o PT-141 age diretamente no cérebro para estimular o desejo sexual, sendo o primeiro e único tratamento aprovado pela FDA que atua por via central para disfunção sexual. Original in PT-BR

PT-141 is catalogued under Sexual / aesthetic. 21 Eagle articles in this library reference this compound.

Category
Sexual / aesthetic
Research stage
FDA approved — FDA Aprovado (Vyleesi) Original in PT-BR
PubMed records
60 (count from PubMed, not curated)
Eagle articles on this compound
21 Eagle articles

Mechanism

Agonista MC4R no SNC — estimula desejo sexual via via central Original in PT-BR

O PT-141 ativa os receptores MC4R no hipotálamo e sistema límbico, regiões cerebrais responsáveis pelo desejo e excitação sexual. Ao contrário dos inibidores de PDE5 (Viagra, Cialis) que atuam no fluxo sanguíneo genital, o PT-141 estimula as vias dopaminérgicas e oxitocinérgicas centrais, promovendo desejo genuíno em vez de apenas resposta vascular. Derivado do Melanotan II, foi modificado para ser mais seletivo ao MC4R, reduzindo efeitos colaterais de pigmentação. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
189691-06-3
Molecular formula
C₅₀H₆₈N₁₄O₁₀
Molecular weight
1025.18 g/mol
Sequence
Nle-Asp-His-DPhe-Arg-Trp-Lys (cíclico) Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Água bacteriostática Original in PT-BR
Stability
Estável reconstituído por 28 dias refrigerado Original in PT-BR
Half-life
~2,5 horas Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
30-45 minutos Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

85/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Melhora significativa no desejo sexual em mulheres com HSDD vs placebo Original in PT-BR

    PMID: 31461144Year: 2019Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Eficácia em disfunção erétil masculina via mecanismo central Original in PT-BR

    PMID: 15505784Year: 2005Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Revisão do sistema melanocortina na regulação do comportamento sexual Original in PT-BR

    PMID: 16422831Year: 2006Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Náusea (~40% dos pacientes — efeito colateral mais frequente)
  • Rubor facial (flushing)
  • Cefaleia
  • Reações no local da injeção

Serious

  • Hipertensão transitória (monitorar PA)
  • Hiperpigmentação facial com uso repetido

Contraindications

  • Hipertensão não controlada
  • Doença cardiovascular ativa
  • Não usar mais de 8 doses por mês

Warnings

  • Náusea intensa pode ocorrer — ter antiemético disponível
  • Não combinar com álcool em excesso

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for PT-141.

Lab tests named in the source

  • PA (pressão arterial)
  • Hormônios sexuais (LH, FSH, testosterona)

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
1,75mg SC Original in PT-BR
Timing
45 min antes da atividade Original in PT-BR
Frequência Máxima
1 dose/24h, máx 8 doses/mês Original in PT-BR
UI Seringa
35UI = 1,75mg (10mg/2mL) Original in PT-BR

Vial sizes: 10mg — Peptide Calculator

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Compatible

Caution

  • Melanotan II

    Mesmo sistema melanocortina. Não combinar — sobreposição de mecanismo e potencialização de efeitos colaterais. Original in PT-BR

Related

View all (21)

← Back to knowledge area